#India #Bengaluru #CAR-T #Immuneel Therapeutics #Applied Cells

Strategic Partnership for Affordable CAR-T Therapies

In a groundbreaking move aimed at revolutionizing cancer treatment, Applied Cells Inc. and Immuneel Therapeutics Private Limited have announced their strategic collaboration on January 13, 2026. This partnership seeks to leverage innovative technology to improve the affordability and accessibility of CAR-T cell therapies in India and around the world.

What the Collaboration Entails

The collaboration framework will see the two companies join forces to evaluate and integrate Applied Cells' MARS® Atlas platform alongside their GoFast™ CAR-T workflow into selected Immuneel CAR-T programs. The primary goal is to significantly reduce the manufacturing costs associated with CAR-T therapies, making them accessible to a broader majority of eligible cancer patients.

Yuchen Zhou, CEO of Applied Cells, expressed his enthusiasm over this partnership, highlighting the potential of combining their technologies with Immuneel's expertise in the Indian regulatory and clinical landscape. This collaboration is poised to bring about a transformation in the CAR-T therapy landscape, potentially allowing millions who currently cannot afford these advanced treatments to access life-saving therapies.

A Shared Vision for Affordability

Both companies envision a future where CAR-T cell therapies can be provided at truly affordable prices without compromising on the therapeutic efficacy that existing approved treatments offer. The emphasis on affordability aligns with Immuneel's mission to make advanced cell therapies accessible for those who need them the most, especially in India, where healthcare affordability is a pressing issue.

Amit Mookim, CEO of Immuneel Therapeutics, reiterated the importance of this collaboration, stating that it represents an essential step towards strengthening their manufacturing capabilities. By exploring innovative technologies like the MARS® Atlas and the GoFast™ workflow, they aim to develop scalable and cost-effective CAR-T solutions that can reach a wider patient base.

The Future of CAR-T Therapy

As they embark on this collaborative effort, both Applied Cells and Immuneel Therapeutics are committed to providing updates on their progress. The companies have already initiated several activities under this partnership, showcasing their commitment to advancing CAR-T therapy through innovative solutions.

Applied Cells has established itself as a leader in automated cell separation and preparation solutions focused on enhancing cell therapy development and manufacturing. Their flagship products, designed to significantly cut down the time and cost of CAR-T manufacturing while keeping quality at the forefront, are at the core of this collaboration.

Immuneel Therapeutics, on the other hand, is a biotechnology firm at the clinical stage, dedicated to delivering best-in-class cell and gene therapies, particularly CAR-T therapies, to cancer patients in India and other emerging markets. Their commitment to building a sustainable ecosystem around cell therapy is integral to expanding access to high-quality treatments at reasonable prices.

Conclusion

The partnership between Applied Cells and Immuneel Therapeutics is a crucial development in the fight against cancer, specifically targeting the barriers associated with the high costs of CAR-T cell therapies. With joint efforts paving the way for innovative manufacturing solutions, patients in India and globally may soon benefit significantly from affordable and accessible CAR-T treatment options.

As these companies continue their work, the hope is that the future will hold a more inclusive healthcare landscape, where advanced therapies are not just a privilege for the few but a possibility for many.